◀ Back to CD79A
CD79A — SRC
Text-mined interactions from Literome
Gazumyan et al., J Exp Med 2006
:
BCR cross linking
resulted in decreased
Src and Syk activation but paradoxically enhanced and prolonged BCR signaling, as measured by cellular tyrosine phosphorylation, Ca ( ++ ) flux, AKT, and ERK activation
Konig et al., Blood 2008
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
SKI-606 effectively inhibited
Bcr-Abl kinase activity in CML CD34 ( + ) cells and
inhibited Src phosphorylation more potently than imatinib
Konig et al., Cancer Res 2008
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
In contrast, Imatinib inhibited only
Bcr-Abl dependent
Src activity
Mahon et al., Cancer Res 2008
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
Two
Src kinase inhibitors ( PP1 and PP2 ) partially removed resistance but did not significantly
inhibit Bcr-Abl tyrosine kinase activity ... In contrast, dasatinib, a dual Bcr-Abl and
Src kinase inhibitor,
inhibited the phosphorylation of both
BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn
Takata et al., FEBS Lett 1995
:
These results demonstrate that the
BCR induced phosphorylation of
Src-PTK is independent of Syk and that the kinase activity of Src-PTK is critical for BCR signaling